Engineered immune cells take aim at Hard-to-Treat leukemia
NCT ID NCT06871410
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 23 times
Summary
This early-phase trial tests a new treatment using specially engineered immune cells (CD83 CAR T cells) for adults with acute myeloid leukemia (AML) that has returned or not responded to standard therapy. The cells are designed to find and destroy leukemia cells while reducing the risk of serious side effects like graft-versus-host disease. The study will enroll 26 participants to evaluate safety, find the best dose, and check for early signs of effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.